BioGaia initiates investigative study in type 2 diabetics
BioGaia has initiated an investigative study in type 2 diabetics together with
Gothia Forum for Clinical Research at Sahlgrenska University Hospital in
Gothenburg in collaboration with Sahlgrenska Center for Cardiovascular and
Metabolic Research.
Based on encouraging findings after supplementation of BioGaia's probiotic
strain Lactobacillus reuteri Protectis in patients with type 2 diabetes in an
earlier pilot study, this double-blind, placebo-controlled study will examine
the effects of Lactobacillus reuteri Protectis supplementation on blood glucose
control over a 12 week period. The study will address both clinical outcome
parameters as well as attempting to define potential mechanistic explanations
for the effects seen.
BioGaia is issuing this press release, as the study will soon become public on
www.clinicaltrials.gov following approval from the ethical committee and
according to requirements of the company. More details regarding the study can
be found on this web site.
- We are at an early stage in the development of products in this potentially
interesting new area for BioGaia. Type 2 diabetes is a huge and growing problem
all over the world, says Peter Rothschild, President, BioGaia.
For additional information please contact
Peter Rothschild, President, telephone: +46 8 555 293 00
Eamonn Connolly, Senior Vice President Research: +46 8 555 293 00
Latest press releases from BioGaia
2012-05-09 Annual General Meeting of BioGaia
2012-05-08 Interim report 1 January-31 March 2012
2012-04-17 BioGaia signs exclusive distribution agreement for its probiotic
drops and tablets in Taiwan
BioGaia has published this information in accordance with the Swedish Securities
Market Act. The information was issued for publication on 14 May 2012, 09:00 am
CET.
[HUG#1611686]
